Department of Gastroenterology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
J Med Ultrason (2001). 2024 Apr;51(2):253-260. doi: 10.1007/s10396-023-01403-x. Epub 2024 Jan 28.
Advances in next-generation sequencing have made comprehensive genomic profiling (CGP) using tumor tissue specimens and liquid biopsy using blood samples feasible in routine clinical practice. In the context of pancreaticobiliary cancer, it is necessary to consider CGP in formulating individualized treatment strategies. Performing CGP with tumor tissue specimens requires a sufficient number of high-quality samples. EUS-guided tissue acquisition (EUS-TA) is expected to play a significant role in this regard, and endosonographers need to address this role. Here, we review the current status of EUS-TA for CGP focusing on pancreatic cancer and biliary tract cancer.
下一代测序技术的进步使得使用肿瘤组织标本进行全面基因组分析（CGP）和使用血液样本进行液体活检在常规临床实践中成为可能。在胰腺胆道癌的背景下，有必要在制定个体化治疗策略时考虑 CGP。使用肿瘤组织标本进行 CGP 需要足够数量的高质量样本。EUS 引导下的组织采集（EUS-TA）有望在这方面发挥重要作用，因此需要超声内镜医师来应对这一角色。在这里，我们回顾了 EUS-TA 在胰腺癌和胆道癌的 CGP 中的应用现状。
